Yu SHI is a Senior Principal Scientist at Bristol Myers Squibb with a background in translational research, focusing on preclinical drug efficacy evaluation and biomarker assay development in the field of oncology. Previously, as a Staff Scientist at Salk Institute for Biological Studies, Yu made significant contributions to understanding the immunomodulatory effects in pancreatic tumor microenvironment and the development of innovative strategies for improving immunotherapy efficacy. With a Ph.D in Genetics & Development from Columbia University, Yu has a strong research background in characterizing intercellular interactions within tumor microenvironments and identifying key factors for translational applications.
June, 2023 - present
December, 2020